Registry study reveals TP53 alteration correlates with higher relapse risk and poorer outcomes in acute myeloid leukemia after hematopoietic stem cell transplantation.
Key Points
Patients with acute myeloid leukemia and TP53 alteration had higher relapse risk and lower overall survival.
Compared to lower-risk groups, the presence of TP53 alteration results in worse outcomes like a 5-year overall survival of only 18%.
Analysis of registry data from adults who underwent transplantation between 2013 and 2019 allowed for comprehensive risk stratification.
Findings highlight the necessity for improved risk stratification strategies in acute myeloid leukemia management.
Cite This Study
Gomez-Arteaga et al. (2025) studied this question.